NZOZ Centurm Medyczne SERAFIN-MED
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At NZOZ Centurm Medyczne SERAFIN-MED in Żarów, the cardiovascular research portfolio focuses on major conditions such as atherosclerotic cardiovascular disease, atrial fibrillation, and multiple forms of heart failure. These trials are designed to test new treatments, reduce serious heart-related events, and improve long-term outcomes for people living with high-risk cardiac conditions.
- Evaluating therapies for elevated lipoprotein(a) and broader atherosclerotic cardiovascular disease
- Studying treatment options for atrial fibrillation with a focus on safety and bleeding risk
- Assessing new approaches for heart failure, including forms linked to obesity, inflammation, and reduced or preserved ejection fraction
These studies aim to improve prevention of cardiovascular complications, support better symptom control, and lower the risk of hospitalization and death.
Nutritional and Metabolic Diseases
The metabolic research at this site centers on obesity, overweight, hypertriglyceridemia, and severe hypertriglyceridemia. The trials are exploring new therapies that may help lower harmful blood fats, support weight-related health, and address metabolic problems that often overlap with cardiovascular disease.
- Testing treatments for obesity and overweight in people at elevated cardiovascular risk
- Evaluating therapies for hypertriglyceridemia and severe hypertriglyceridemia
- Exploring whether metabolic treatments can also improve kidney outcomes and reduce cardiovascular complications
Overall, this research aims to refine treatment strategies for patients whose metabolic disorders may contribute to broader heart and kidney health concerns.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Centurm Medyczne SERAFIN-MED
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2024-10-18 | 2025-08-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.